These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24652679)

  • 81. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.
    Schapansky J; Nardozzi JD; LaVoie MJ
    Neuroscience; 2015 Aug; 302():74-88. PubMed ID: 25284317
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis.
    Cabezudo D; Tsafaras G; Van Acker E; Van den Haute C; Baekelandt V
    Acta Neuropathol; 2023 Aug; 146(2):245-261. PubMed ID: 37289222
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
    Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW
    PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252
    [TBL] [Abstract][Full Text] [Related]  

  • 84. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain.
    Herzig MC; Bidinosti M; Schweizer T; Hafner T; Stemmelen C; Weiss A; Danner S; Vidotto N; Stauffer D; Barske C; Mayer F; Schmid P; Rovelli G; van der Putten PH; Shimshek DR
    PLoS One; 2012; 7(5):e36581. PubMed ID: 22615783
    [TBL] [Abstract][Full Text] [Related]  

  • 85. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
    Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
    Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Sleep aspects on video-polysomnography in LRRK2 mutation carriers.
    Ehrminger M; Leu-Semenescu S; Cormier F; Corvol JC; Vidailhet M; Debellemaniere E; Brice A; Arnulf I
    Mov Disord; 2015 Nov; 30(13):1839-43. PubMed ID: 26468079
    [TBL] [Abstract][Full Text] [Related]  

  • 88. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
    Loeffler DA; Aasly JO; LeWitt PA; Coffey MP
    J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The synaptic function of LRRK2.
    Lee S; Imai Y; Gehrke S; Liu S; Lu B
    Biochem Soc Trans; 2012 Oct; 40(5):1047-51. PubMed ID: 22988863
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inflammatory profile in LRRK2-associated prodromal and clinical PD.
    Brockmann K; Apel A; Schulte C; Schneiderhan-Marra N; Pont-Sunyer C; Vilas D; Ruiz-Martinez J; Langkamp M; Corvol JC; Cormier F; Knorpp T; Joos TO; Gasser T; Schüle B; Aasly JO; Foroud T; Marti-Masso JF; Brice A; Tolosa E; Marras C; Berg D; Maetzler W
    J Neuroinflammation; 2016 May; 13(1):122. PubMed ID: 27220776
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Non-motor and motor features in LRRK2 transgenic mice.
    Bichler Z; Lim HC; Zeng L; Tan EK
    PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.
    Russo I; Berti G; Plotegher N; Bernardo G; Filograna R; Bubacco L; Greggio E
    J Neuroinflammation; 2015 Dec; 12():230. PubMed ID: 26646749
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
    Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
    PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy.
    Su YC; Guo X; Qi X
    Biochim Biophys Acta; 2015 Jan; 1852(1):12-21. PubMed ID: 25446991
    [TBL] [Abstract][Full Text] [Related]  

  • 96. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
    Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
    Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
    [TBL] [Abstract][Full Text] [Related]  

  • 97. LRRK2 signaling pathways: the key to unlocking neurodegeneration?
    Berwick DC; Harvey K
    Trends Cell Biol; 2011 May; 21(5):257-65. PubMed ID: 21306901
    [TBL] [Abstract][Full Text] [Related]  

  • 98. LRRK2 dephosphorylation increases its ubiquitination.
    Zhao J; Molitor TP; Langston JW; Nichols RJ
    Biochem J; 2015 Jul; 469(1):107-20. PubMed ID: 25939886
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?
    Grünewald A; Arns B; Meier B; Brockmann K; Tadic V; Klein C
    Antioxid Redox Signal; 2014 May; 20(13):1955-60. PubMed ID: 24251413
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
    Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
    Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.